| Name | Title | Contact Details |
|---|
Cardinal Analytx Solutions brings together distinguished innovators and leaders collaboratively advancing into new territory to substantially address one of the most pressing human and economic challenges of our time.
Christiana Care Health System is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pullman Regional Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pullman, WA. To find more information about Pullman Regional Hospital, please visit www.pullmanregional.org
inVentiv Health, Inc. provides value-added services to the pharmaceutical, life sciences, and healthcare industries. The Company operates in four segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. The Company supports a range of clinical development, communications and commercialization activities that are critical to its customers' ability to complete the development of drug products and medical devices and commercialize them. In addition, the Company provides medical cost containment services to payors in its patient outcomes business. inVentiv provides services to over 350 client organizations, including global pharmaceutical companies, emerging and specialty biotechnology companies, and payors.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic